© National Cancer Institute
|
About the disease |
Acute myelogenous leukemia (AML) is a progressively rapid blood and bone marrow cancer that affects granulocytes or white blood cells.i, ii |
|
Cause |
Although the exact cause of AML is unclear, several risk factors exist. These include |
|
Diseaseburden |
AML can affect both children and adults. Estimates suggest there are more than 13,000 new cases annually in the US alone.iii |
|
Vaccine status |
In development for the treatment of acute myelogenous leukemia. |
|
Reference |
i. US Centers for Disease Control and Prevention. Blood Cancers. ii. US Centers for Disease Control and Prevention. Leukemia. iii. US National Cancer Institute. What You Need To Know About™ Leukemia. |
10 May 2012,
New report offers a blueprint to boost research and development (R&D) for diseases of the...
01 March 2012,
Expanded Code of Practice for pharmaceutical industry updates ethical and professional standards...
30 January 2012,
Research-based pharmaceutical industry pledges 14 billion treatments to help end nine neglected...
21 May 2012, Geneva, Switzerland
The Annual IFPMA Reception on the occasion of the 65th World Health Assembly
03 May 2012, Accra, Ghana
3rd African Regulatory Conference (ARC) - Partnering for earlier access to good quality medicines...
IFPMA Developing World Health Partnerships Directory
Your source for the research-based pharmaceutical industry’s long-term health partnerships programs...

IFPMA Clinical Trials Portal
Your source for clinical trials information on the Web. Find ongoing and completed trials of new...

IFPMA Code of Practice
Expanded IFPMA Code of Practice updates ethical and professional standards for interacting with...
